Omeros succeeds in Nasdaq listing
This article was originally published in Scrip
Executive Summary
Omeros has ended its near two-year wait to float on the stock market after it raised $68.2 million in an IPO. The firm sold 6.8 million shares at $10 each to fund the development of its anti-inflammatory and ophthalmic candidates for use in surgery.